Artios
A UK-based biotech established in May 2016 to develop a next generation DNA Damage Response (DDR) target pipeline with the potential to transform cancer therapy.
Artios has in-licensed its lead DDR program, PolƟ, from Cancer Research UK (CRUK) and continues to work with CRUK and other experts in the field to build its pipeline of novel DDR programs.
The company's chief executive, Niall Martin, played a major role in the AstraZeneca blockbuster PARP inhibitor Lynparza (olaparib), which has validated DDR targeted products.
Latest Artios News & Features
3 December 2020
6 November 2019
24 September 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze